| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
* To whom correspondence should be addressed. E-mail: xyan{at}caregroup.harvard.edu.
The angiotensin II type 2 (AT2) receptor is upregulated in the left ventricle (LV) in heart failure, but its pathophysiologic roles in vivo are not understood. In the present study, AT2 receptors were expressed in transgenic (TG) mice using the ventricular-specific myosin light chain (MLC2v) promoter. In TG compared with nontransgenic (NTG) mice, in vivo LV systolic pressure and peak +dP/dt were depressed, while LV diastolic pressure was elevated (p<0.05). Echocardiography showed severely depressed LV fractional shortening, increased systolic and diastolic dimensions, and wall thinning (p<0.05). Confocal and electron microscopy studies demonstrated an increase in the size of myocytes and interstitial spaces as well as an increase in interstitial collagen, disruption of the Z-band, and changes in cytochrome C localization. The changes were most prominent in the highest expressing TG line, implying a dose response relationship. AT2 overexpression was also directly associated with the increase of phosphorylated protein levels of PKC
,PKC
,and p70 S6K. These data demonstrate that ventricular myocyte-specific expression of AT2 receptors promotes the development of dilated cardiomyopathy and heart failure in vivo.
This article has been cited by other articles:
|
|
 |
|
  B. S. Huang, M. Ahmad, J. Tan, and F. H. H. Leenen Chronic central versus systemic blockade of AT1 receptors and cardiac dysfunction in rats post-myocardial infarction Am J Physiol Heart Circ Physiol, September 1, 2009; 297(3): H968 - H975. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. R. Porrello, A. D'Amore, C. L. Curl, A. M. Allen, S. B. Harrap, W. G. Thomas, and L. M.D. Delbridge Angiotensin II Type 2 Receptor Antagonizes Angiotensin II Type 1 Receptor-Mediated Cardiomyocyte Autophagy Hypertension, June 1, 2009; 53(6): 1032 - 1040. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Yan, A. J. T. Schuldt, R. L. Price, I. Amende, F.-F. Liu, K. Okoshi, K. K. L. Ho, A. J. Pope, T. K. Borg, B. H. Lorell, et al. Pressure overload-induced hypertrophy in transgenic mice selectively overexpressing AT2 receptors in ventricular myocytes Am J Physiol Heart Circ Physiol, March 1, 2008; 294(3): H1274 - H1281. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Philipp, C. Broschk, A. Vollmar, and O. Distl Evaluation of Tafazzin as Candidate for Dilated Cardiomyopathy in Irish Wolfhounds J. Hered., July 9, 2007; (2007) esm045v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Strauss and A. S. Hall Angiotensin Receptor Blockers May Increase Risk of Myocardial Infarction: Unraveling the ARB-MI Paradox Circulation, August 22, 2006; 114(8): 838 - 854. [Full Text] [PDF]
|
|
|
|
|
|
B. Molavi, J. Chen, and J. L. Mehta Cardioprotective effects of rosiglitazone are associated with selective overexpression of type 2 angiotensin receptors and inhibition of p42/44 MAPK Am J Physiol Heart Circ Physiol, August 1, 2006; 291(2): H687 - H693. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D'Amore, M. J. Black, and W. G. Thomas The Angiotensin II Type 2 Receptor Causes Constitutive Growth of Cardiomyocytes and Does Not Antagonize Angiotensin II Type 1 Receptor-Mediated Hypertrophy Hypertension, December 1, 2005; 46(6): 1347 - 1354. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. W. Booz Putting the Brakes on Cardiac Hypertrophy: Exploiting the NO-cGMP Counter-Regulatory System Hypertension, March 1, 2005; 45(3): 341 - 346. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Nakayama, X. Yan, R. L. Price, T. K. Borg, K. Ito, A. Sanbe, J. Robbins, and B. H. Lorell Chronic ventricular myocyte-specific overexpression of angiotensin II type 2 receptor results in intrinsic myocyte contractile dysfunction Am J Physiol Heart Circ Physiol, January 1, 2005; 288(1): H317 - H327. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Hafizi, X. Wang, A. H. Chester, M. H. Yacoub, and C. G. Proud ANG II activates effectors of mTOR via PI3-K signaling in human coronary smooth muscle cells Am J Physiol Heart Circ Physiol, September 1, 2004; 287(3): H1232 - H1238. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Johren, A. Dendorfer, and P. Dominiak Cardiovascular and renal function of angiotensin II type-2 receptors Cardiovasc Res, June 1, 2004; 62(3): 460 - 467. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. W. Booz Cardiac Angiotensin AT2 Receptor: What Exactly Does It Do? Hypertension, June 1, 2004; 43(6): 1162 - 1163. [Full Text] [PDF]
|
|
|
|
|
|
M. Brede, W. Roell, O. Ritter, F. Wiesmann, R. Jahns, A. Haase, B. K. Fleischmann, and L. Hein Cardiac Hypertrophy Is Associated With Decreased eNOS Expression in Angiotensin AT2 Receptor-Deficient Mice Hypertension, December 1, 2003; 42(6): 1177 - 1182. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |
